Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol
The introduction of (m)FOLFIRINOX and gemcitabine-nab-paclitaxel has changed the perspective for patients with locally advanced pancreatic cancer (LAPC). Consequently, in experienced centres 23% of patients with LAPC undergo a resection with 5-year overall survival (OS) rates of up to 25%. In the Ne...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February 19, 2025
|
| In: |
BMC cancer
Year: 2025, Volume: 25, Pages: 1-12 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-025-13554-w |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-025-13554-w |
| Author Notes: | T.F. Stoop, L.W.F. Seelen, F.R. van ’t Land, A.C. van der Hout, J.C.M. Scheepens, M. Ali, A.M. Stiggelbout, B.M. van der Kolk, B.A. Bonsing, D.J. Lips, D.J.A. de Groot, E. van Veldhuisen, E.D. Kerver, E.R. Manusama, F. Daams, G. Kazemier, G.A. Cirkel, G. van Tienhoven, G.A. Patijn, H.N. Lelieveld-Rier, I.H. de Hingh, I.E.G. van Hellemond, J.H. Wijsman, J.I. Erdmann, J.S.D. Mieog, J. de Vos-Geelen, J.W.B. de Groot, K.R.D. Lutchman, L.J. Mekenkamp, L.W. Kranenburg, L.P.M. Beuk, M. W. Nijkamp, M. den Dulk, M.B. Polée, M.Y.V. Homs, M.L. Wumkes, M.W.J. Stommel, O.R. Busch, R.F. de Wilde, R.T. Theijse, S.A.C. Luelmo, S. Festen, T.L. Bollen, U.P. Neumann, V.E. de Meijer, W.A. Draaisma, B. Groot Koerkamp, I.Q. Molenaar, C.L. Wolfgang, M. Del Chiaro, M.G.H. Katz, T. Hackert, J.A.C. Rietjens, J.W. Wilmink, H.C. van Santvoort, C.H.J. van Eijck, M.G. Besselink and for the Dutch Pancreatic Cancer Group |
| Summary: | The introduction of (m)FOLFIRINOX and gemcitabine-nab-paclitaxel has changed the perspective for patients with locally advanced pancreatic cancer (LAPC). Consequently, in experienced centres 23% of patients with LAPC undergo a resection with 5-year overall survival (OS) rates of up to 25%. In the Netherlands, the nationwide resection rate for LAPC remains low at 8%. The PREOPANC-4 program aims for a nationwide implementation of the international multidisciplinary best-practice to improve patient outcome. |
|---|---|
| Item Description: | the Dutch Pancreatic Cancer Group: A. Bruynzeel, A. Vlijm, A. van Asseldonk, B. Zonderhuis, A.A. Javed, A. Sterk, A. Schoorlemmer, A. Stam, C.Y. Nio, E. van Alphen, H.W.M. van Laarhoven, H. van Veenendaal, I. Griffioen, I.F. Rompen, J.M. Klaase, M. Los, M.F.M.A. Marting, M.S.L. Liem, J. Peters, L.J. Peters, Linda Garms, M. Walma, L.H.J. Brada, M. Seijbel, N.D. Hildebrand, N. Michiels, R. Bax, R.M. van Dam, S. Achten, S. Bouwense, S. Augustinus, S. Rötgerink, T.W. van Ravens, V.B. Nieuwenhuijs, W.W. te Riele Online veröffentlicht am 19. Februar 2015 Gesehen am 09.12.2025 |
| Physical Description: | Online Resource |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-025-13554-w |